Ticker Details
Travere Therapeutics, Inc.
IPO Date:	August 15, 2003
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$6.19B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.61 | 2.91%
Avg Daily Range (30 D):	$1.22 | 2.10%
Avg Daily Range (90 D):	$1.13 | 2.25%

Institutional Daily Volume
Avg Daily Volume:	1.07M
Avg Daily Volume (30 D):	1.24M
Avg Daily Volume (90 D):	1.76M

Trade Size
Avg Trade Size (Sh.):	79
Avg Trade Size (Sh.) (30 D):	58
Avg Trade Size (Sh.) (90 D):	68

Institutional Trades
Total Institutional Trades:	4,709
Avg Institutional Trade:	$2.46M
Avg Institutional Trade (30 D):	$4.38M
Avg Institutional Trade (90 D):	$3.88M
Avg Institutional Trade Volume:	.11M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$4.01M
Avg Closing Trade (30 D):	$12.17M
Avg Closing Trade (90 D):	$14.84M
Avg Closing Volume:	183.64K

News

Jul 17, 2026 @ 1:43 AM Kuehn Law Encourages Investors of Travere Therapeu... Source: Kuehn Law, Pllc

Jul 17, 2026 @ 1:16 AM Kuehn Law Encourages Investors of Rhythm Pharmaceu... Source: Kuehn Law, Pllc

May 10, 2026 @ 1:16 PM Validating headline phrasing and editorial resonan... Source: Seena Hassouna

Feb 27, 2026 @ 2:52 PM Your Kidneys Count: American Kidney Fund Urges Ame... Source: American Kidney Fund

Jan 31, 2026 @ 1:50 AM TVTX ALERT: Investigation Launched into Travere Th... Source: Robbins Geller Rudman & Dowd Llp

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-.46	$-.37	$-.4
Diluted EPS	$-.47	$-.37	$-.4
Revenue	$591.33M	$169.58M	$127.2M
Gross Profit	$583.07M	$167.41M	$125.25M
Net Income / Loss	$-43.46M	$-34.8M	$-37.1M
Operating Income / Loss	$-40.46M	$3.95M	$-36.92M
Cost of Revenue	$8.26M	$2.17M	$1.95M
Net Cash Flow	$42.58M	$39.37M	$-14.67M
PE Ratio

Splits
Nov 08, 2011	1:9